CABALETTA BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.32 USD | -6.31% |
|
-23.46% | -55.09% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presenter SpeechUnknown Analyst (Analysts)Thanks, everyone. We'll get started now. Good aftern...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.01
USD
Average target price
34.5
USD
Spread / Average Target
+213.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.09% | 531M | |
| -2.90% | 103B | |
| +1.23% | 95.28B | |
| +1.46% | 22.15B | |
| -16.03% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.51% | 16.05B | |
| +4.81% | 13.68B | |
| +32.94% | 12.17B |
- Stock Market
- Equities
- CABA Stock
- News Cabaletta Bio, Inc.
- Transcript : Cabaletta Bio, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05
